Jeff Marrazzo has led the creation and growth of Spark Therapeutics from a research center within the Children's Hospital of Philadelphia to a fully integrated gene therapy company that is challenging the inevitability of genetic disease by discovering, developing and delivering potential treatments in ways unimaginable – until now. He also serves on Spark’s board of directors.
Under Jeff's leadership, Spark has successfully completed the first randomized, controlled Phase 3 trial of an investigative gene therapy for a genetic disease and established human proof-of-concept of Spark’s gene therapy platform in both the retina and the liver. The company is currently preparing the first Biologics License Application submission for a gene therapy for a genetic disease in the U.S. In the three years since founding Spark, Jeff has raised more than $500 million in capital, established a global collaboration with Pfizer, and built an organization of nearly 200 colleagues.
During a career that has spanned the public and private sectors, Jeff has consistently championed the potential benefits of precision medicine and healthcare reform for patients. Prior to Spark, he helped build and sell the first genetic testing benefit management and pharmacogenomics medicines company to CVS Caremark. Previously, Jeff served as an advisor to former Pennsylvania Governor Edward G. Rendell, where he led reforms in the financing and delivery of healthcare.
Jeff received a B.A. in economics and B.S.E. in systems science and engineering from the University of Pennsylvania. He also holds a dual M.B.A. / M.P.A. from The Wharton School of the University of Pennsylvania and Harvard University, a program which he founded.